Skip to content
Clinical Trials – home
Not yet recruiting

Efficacy and Safety of ADEZUNAP (AP707) in Adults with Fibromyalgia Syndrome – Phase II Placebo‑Controlled Washout Study

Verified siteInvestigational
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

What is this trial about?

A plain-language summary of the goals, design and what participants do

Fibromyalgia syndrome is a long‑lasting condition that causes widespread muscle pain, tiredness, and problems with sleep. The study will test a new oral spray called AP707, whose active ingredient is adezunap, and compare it with a placebo that looks the same but does not contain the active drug.

The main aim of the trial is to see whether the medication can reduce the level of pain and improve other symptoms of the condition. After a short “washout” period, during which participants stop other pain medicines, they will receive either the study drug or the placebo for several weeks. Throughout the study, participants will attend a few clinic visits where they will rate their pain on a simple 0‑to‑10 scale, answer questions about daily function, and have basic health checks such as blood pressure and blood tests.

The research process

The trial runs in 7 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Enrollment and Randomization

    After giving consent, you are assigned at random to receive either the study drug AP707 or a matching placebo.

    The assignment is kept secret to ensure the study remains unbiased.

  2. Step 2

    Baseline Assessment (Visit 3)

    You complete a series of questionnaires that measure pain intensity, overall fibromyalgia impact, sleep quality, mood, and quality of life.

    A health professional records your vital signs, performs a physical examination, and takes blood samples to check liver and kidney function.

    These measurements create a reference point for all later comparisons.

  3. Step 3

    Start of Study Medication

    You begin using an oral mucosal spray containing adezunap at a dose of 19.8 mg per administration, or you receive an identical‑looking spray without active drug (placebo).

    The spray is taken as instructed by the study team, typically once daily, for the duration of the treatment period.

    You are asked to keep a diary of each dose and any symptoms you experience.

  4. Step 4

    Mid‑Treatment Monitoring (Visit 5)

    Approximately halfway through the treatment period, you return for a follow‑up visit.

    The same questionnaires, vital‑sign checks, and blood tests are repeated to monitor safety and any changes in pain or other symptoms.

    The study staff reviews your medication diary and asks about any side effects.

  5. Step 5

    End‑of‑Treatment Evaluation (Visit 7)

    At the final treatment visit, you again complete all questionnaires and undergo the same physical and laboratory examinations.

    The primary outcome is the change in the weekly average pain rating (Pain‑NRS) from the baseline visit to this visit.

    Additional outcomes include changes in sleep, mood, functional status, and laboratory values.

  6. Step 6

    Washout Period

    After the last dose of study medication, you stop taking the spray and enter a washout phase during which no study drug is given.

    The purpose of this period is to allow any effects of the medication to wear off before the final follow‑up.

  7. Step 7

    Final Follow‑Up Visit

    Several weeks after the washout begins, you attend a final visit to assess long‑term safety.

    Pain scores, questionnaires, vital signs, and blood tests are repeated one last time.

    The study team records any adverse events that may have occurred during the entire trial.

Who can join the trial?

9 criteria

  • Be able to understand what the study involves, follow the directions and questions, sign the consent form, and agree to follow the study rules.
  • Be between 18 and 99 years old and, according to the doctor, expected to live at least one more year.
  • Have a confirmed diagnosis of fibromyalgia based on the 2016 criteria, which means:
    • Feeling pain in at least four of five major body areas (called generalized pain).
    • Having those symptoms at a similar level for at least three months.
    • Scoring on the assessment tools as either:

      • a Widespread Pain Index (WPI) of 7 or higher and a Symptom Severity Scale (SSS) score of 5 or higher, or
      • a WPI of 4‑6 and an SSS score of 9 or higher.
      • The diagnosis is accepted even if other medical conditions are also present.
      • Experience moderate to severe pain at the time of screening, shown by an average rating of 4 to 9 on a 0‑10 Numeric Rating Scale (NRS) during the past four weeks.
      • Use a reliable birth‑control method that fails less than 1 % of the time from the start of the study until its end, unless you cannot become pregnant (for example, if you are post‑menopausal, have had surgery that makes you unable to have children, or are in a stable same‑sex relationship).

Who cannot join the trial?

12 criteria

  • History of hypersensitivity (allergic reaction) or intolerance to the investigational medicinal product (IMP) or its ingredients, including substances similar to cannabinoids or cannabis products.
  • Known liver disease or blood tests showing liver enzymes (ALT = alanine aminotransferase, AST = aspartate aminotransferase, alkaline phosphatase) higher than 2.5 times the normal range, or bilirubin (a pigment from red blood cells) higher than 1.5 times the normal range at screening.
  • Known kidney disease or blood test showing serum creatinine (a waste product measured to check kidney function) higher than 1.5 times normal, or an estimated glomerular filtration rate (a measure of how well kidneys filter blood) below 60 mL/min/1.73 m² at screening.
  • Body Mass Index (BMI) less than 18 or greater than 40 kg/m² at screening. BMI is a calculation using height and weight to assess body size.
  • Use of cannabinoids (substances found in cannabis) within 8 weeks before screening.
  • Participation in another interventional clinical trial (a study testing a new treatment) within 4 weeks before screening.
  • Females who are currently pregnant or lactating (breastfeeding), or who plan to become pregnant during the study.
  • Being an investigator, study staff, sponsor, their immediate family members, or belonging to a vulnerable population (for example, people under legal guardianship or who are imprisoned).
  • Any medical or psychiatric condition that the doctor believes would put you at risk, prevent you from following the study rules, or stop you from completing the trial.
  • Any infectious or inflammatory disease, or neurological or psychiatric disorder that the doctor thinks could interfere with the assessment of fibromyalgia.
  • Diagnosis of severe depression or a DASS‑21 depression score of 21 or higher at screening. Only selective serotonin reuptake inhibitors (SSRIs) are allowed as antidepressants, and they must have been stable for at least 3 months.
  • History of malignancy (cancer) within the past 5 years, except for fully removed basal cell or squamous cell skin cancer with no recurrence, or treated carcinoma in‑situ of the cervix.
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not yet recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

AP707 is an experimental medication being tested for the treatment of fibromyalgia. It is given as an oral spray or suspension that is placed in the mouth, where it is absorbed through the lining of the mouth. The drug contains an active ingredient called adezunap, which is being studied to see if it can reduce the widespread pain, fatigue, and sleep problems that people with fibromyalgia often experience. In this trial, participants receive AP707 to find out whether it can safely improve their symptoms compared with not receiving the active drug.

What is already known about the treatment

  • Placebo

    This is an inert oral spray/suspension used only as a control in the study. It contains no active drug and therefore has no therapeutic effect or approved medical use. Placebos are commonly employed in clinical trials to compare the effects of the real medication. Because it has no active ingredient, it has no mechanism of action or pharmacological class.

  • AP707

    AP707 is an oral mucosal spray/suspension delivering 19.8 mg of adezunap, taken by spraying onto the inside of the mouth. The product is currently in a phase II clinical trial and has not yet been approved for any medical use. It is being tested to relieve the pain and other symptoms of fibromyalgia syndrome. Adezunap works by modulating pain‑signaling molecules in the nervous system, and it is classified as a non‑opioid analgesic (ATC code N02BG10).

Investigated diseases

Fibromyalgia syndrome - Fibromyalgia syndrome is a long‑lasting condition marked by widespread muscle and joint pain that is felt all over the body. People with the disorder often notice that the pain worsens after physical activity, stress, or changes in weather. The condition is also linked with increased tiredness, sleep problems, and difficulties concentrating, sometimes called “fibro‑fog.” Symptoms tend to develop gradually and may become more intense over months or years, with periods of relative improvement followed by flare‑ups. The pain and other symptoms can spread to new areas of the body as the condition progresses.
Trial detailsLast updated 21 Nov 2026
Age18+ yearsPhasePhase IITrial ID2025-522891-10-00Protocol codeREPLACE-1Estimated enrolment226 patientsSponsorApurano Pharmaceuticals GmbH

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.